| scholarly article | Q13442814 |
| P2093 | author name string | Qiang Liu | |
| Yinghua Zhu | |||
| Fengxi Su | |||
| Yujie Liu | |||
| Erwei Song | |||
| Lijuan Sun | |||
| Chang Gong | |||
| Xiaobin Lv | |||
| Bodu Liu | |||
| Junjun Chu | |||
| Yanqin Wu | |||
| Pengnan Hu | |||
| P2860 | cites work | DNA-damage response control of E2F7 and E2F8 | Q24306816 |
| Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase | Q71761161 | ||
| miR-15 and miR-16 induce apoptosis by targeting BCL2 | Q24536069 | ||
| Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 | ||
| MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 | Q24648241 | ||
| MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E | Q28117082 | ||
| miR-15a and miR-16-1 in cancer: discovery, function and future perspectives | Q28247489 | ||
| The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities | Q28297958 | ||
| E2F7 represses a network of oscillating cell cycle genes to control S-phase progression | Q28592916 | ||
| Cross-study validation and combined analysis of gene expression microarray data | Q31129354 | ||
| Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen | Q33337206 | ||
| An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients | Q33519584 | ||
| Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer | Q33555064 | ||
| PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer | Q33933172 | ||
| An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival | Q33939753 | ||
| Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors | Q34363866 | ||
| Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients | Q34597068 | ||
| Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL | Q34650759 | ||
| Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. | Q35218111 | ||
| MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells | Q35643732 | ||
| High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer | Q36070061 | ||
| Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression | Q37112680 | ||
| MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma | Q37262390 | ||
| Biological determinants of endocrine resistance in breast cancer | Q37585095 | ||
| Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer | Q39363790 | ||
| E2F7 can regulate proliferation, differentiation, and apoptotic responses in human keratinocytes: implications for cutaneous squamous cell carcinoma formation | Q39882791 | ||
| E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1. | Q40113861 | ||
| Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells | Q40670668 | ||
| Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen | Q41160149 | ||
| Modulation of the growth-inhibitory effects of progestins and the antiestrogen hydroxyclomiphene on human breast cancer cells by epidermal growth factor and insulin | Q41290624 | ||
| Changes in apoptosis, mitosis, Her-2, p53 and Bcl2 expression in breast carcinomas after short-term tamoxifen treatment. | Q44043956 | ||
| Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. | Q44093400 | ||
| Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. | Q44534514 | ||
| The 2000 EBCTCG overview: a widening gap. | Q44788235 | ||
| Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase | Q45309214 | ||
| A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. | Q52032770 | ||
| The prognostic ease and difficulty of invasive breast carcinoma. | Q53256620 | ||
| microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer | Q58211596 | ||
| Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer | Q69856765 | ||
| P433 | issue | 31 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tamoxifen | Q412178 |
| overexpression | Q61643320 | ||
| P304 | page(s) | 31944-31957 | |
| P577 | publication date | 2015-09-12 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter | |
| P478 | volume | 6 |
| Q49912442 | A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen |
| Q91596428 | Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer? |
| Q62785312 | ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors |
| Q55315668 | Expression patterns of E2F transcription factors and their potential prognostic roles in breast cancer. |
| Q57075023 | Expressions and prognostic values of the transcription factors in human breast carcinoma |
| Q55000578 | Functional miRNAs in breast cancer drug resistance. |
| Q64093800 | Gsslasso Cox: a Bayesian hierarchical model for predicting survival and detecting associated genes by incorporating pathway information |
| Q38652482 | MiR-15a/16 deficiency enhances anti-tumor immunity of glioma-infiltrating CD8+ T cells through targeting mTOR. |
| Q52655389 | MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7. |
| Q93018182 | Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs |
| Q48171311 | Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer |
| Q57136038 | Pancreatic cancer survival analysis defines a signature that predicts outcome |
| Q92906831 | Prediction of Disease-related microRNAs through Integrating Attributes of microRNA Nodes and Multiple Kinds of Connecting Edges |
| Q93379565 | Prognostic values of E2F mRNA expression in human gastric cancer |
| Q33850064 | Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators |
| Q95642313 | SNHG7 Contributes to the Progression of Non-Small-Cell Lung Cancer via the SNHG7/miR-181a-5p/E2F7 Axis |
| Q53692325 | Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. |
| Q92191083 | Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms |
| Q99590082 | The 3D Genomic Landscape of Differential Response to EGFR/HER2 Inhibition in Endocrine-Resistant Breast Cancer Cells |
| Q90568606 | The Regulatory Role of MicroRNAs in Breast Cancer |
| Q36666943 | miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites |
Search more.